Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    FDA Classifies Computerized Cognitive Assessment Aid Into Class II

    In the August 17, 2015, Federal Register, FDA announced it has classified the computerized cognitive assessment aid into class II (special controls) medical device.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Classifies EGR1 Gene Fish Test As Class II Device

    In the September 3, 2014, Federal Register, FDA issued a final order classifying early growth response 1 ("EGR1") gene fluorescence in-situ hybridization ("FISH") test system for specimen characterization into class II (special controls).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
Jones Day
  • Article

    FDA Corrects Notice Of Independent Assessment Of The Process For The Review Of Device Submissions

    The May 29 notice was issued earlier than intended, and the June 12 correction notes that the documents will instead be available on June 11.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Establishes Public Docket On Treatments For Duchenne Muscular Dystrophy

    In the September 4, 2014, Federal Register, FDA announced its establishment of a public docket to discuss issues related to developing drugs for Duchenne Muscular Dystrophy.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA, Global Regulators Team Up To Advance Ebola Treatments

    A coalition of pharmaceutical regulators came together earlier this month in hopes of finding a medical solution to the Ebola virus outbreak in West Africa.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Issues Final Rule On Symbols In Labeling

    In the June 15, 2016, Federal Register, FDA issued a final rule revising the Agency's medical device and certain biological product labeling regulations.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Issues Reproposal Of Proposed Rule To Classify Certain Diagnostic Devices For Bacillus Detection Into Class II

    In the November 17, 2015, Federal Register, FDA issued a reproposal of a proposed rule to classify IVD devices for Bacillus species (spp.) detection into class II (special controls)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Leads The Way On Fluoropolymers

    On August 6, 2025, the U.S. Food and Drug Administration (FDA) became the latest governmental agency to confirm that fluoropolymers are both safe and necessary. After an independent safety review...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Akin
    Akin
  • Article

    FDA Moves Forward On Fluoropolymers

    On August 6, 2025, the U.S. Food and Drug Administration (FDA) became the latest governmental agency to confirm that fluoropolymers are both safe and necessary.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Akin
    Akin
  • Article

    FDA Proposes Reclassification Of Transvaginal Pelvic Surgical Mesh As Class III Device

    The FDA issued a proposal to reclassify surgical mesh for transvaginal pelvic organ prolapse repair from class II to class III.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Proposes To Amend Regulations For Embryo Donation And Related Labeling

    In the December 31, 2015, Federal Register, FDA proposed amendments to the human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulations regarding donor eligibility and related labeling for human embryos.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Public Workshop On Patient, Medical Professional Perspectives On Receiving Genetic Test Results (March 2)

    On March 2, 2016, the FDA is hosting a public workshop on "Patient and Medical Professional Perspectives on the Return of Genetic Test Results."
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    FDA Releases "Purple Book," Including Biosimilar Products

    The FDA’s new "Purple Book" lists biological products licensed by FDA under the Public Health Service Act (the PHS Act).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    FDA Requests Nominations For Science Board

    In the January 23, 2015, Federal Register, FDA requested nominations for members to serve on the Science Board to the FDA's Office of the Commissioner, Office of the Chief Scientist.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Solicits Comments On Request For 510(K) Exemption For Wheelchair Elevator

    FDA requested comments on a petition requesting exemption from the premarket notification requirements for a wheelchair elevator device.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Solicits Nominations For Science Board

    The Science Board provides advice to the Commissioner and other appropriate officials on specific complex scientific and technical issues important to FDA and its mission, including emerging issues within the scientific community.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Federal Sunshine Act Reporting Requirements Expanded To Other Prescribers

    Because this change applies to all data submitted on or after January 1, 2022, companies must begin collecting reportable data on January 1, 2021.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Cooley LLP
    Cooley LLP
  • Article

    Final HIPAA Rule Gives Patients Right To Access Test Results Directly From Labs

    On February 6, 2014, the Department of Health & Human Services published a final rule making changes to the Clinical Laboratory Improvement Amendments of 1988 and Health Insurance Portability and Accountability Act of 1996.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    For Clinical Trial Recruiting, Words Matter

    In a recent publication we helped co-author, we examined ClinicalTrials.gov entries and their possible impact on informing potential subjects of their eligibility to participate in clinical trials.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Free, Discounted, And Value-Added Items And Services Offered By Manufacturers And Providers To Referral Sources: Problematic Inducement Or Permissible Assistance? (Video)

    In an effort to limit challenges for patient access, patient adherence to recommended treatment, or adoption of innovative products and services, providers, suppliers, and product manufacturers seek ways to address such roadblocks.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Showing 121–140 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics